Merck poised for breakout via strategic acquisitions
Merck's 'string of pearls' M&A strategy effectively mitigates its looming Keytruda patent cliff, making the stock undervalued at current multiples.
Keep reading this one
You've read the thesis and who argued it. A free account opens the argument, what validates it, the risks the show raised, and the moment in the episode where it was said — 3 ideas in full a day, no card.